Imipramine: Clinical Overview
Imipramine is a tricyclic antidepressant with limited modern indications, primarily reserved as third-line therapy for childhood enuresis when first-line treatments fail, with significant cardiotoxicity concerns requiring mandatory ECG screening before initiation.
Primary Indication
Childhood Enuresis (Third-Line Therapy)
Imipramine should only be used for enuresis after failure of alarm therapy and when desmopressin is unaffordable or has failed 1. This represents the most evidence-based modern use, though it carries substantial safety concerns that relegate it to tertiary care facilities 1.
Dosing Recommendations
For Enuresis (Pediatric)
- 25 mg at bedtime for children ≤9 years
- 50 mg at bedtime for children >9 years
- Maximum dose: 2.5 mg/kg/day - this should never be exceeded in children 2
- Evaluate response after 1 month 1
- If partial response occurs, may add desmopressin with strict evening/nighttime fluid restriction 1
- Treatment duration: 4-6 months if effective 3
- Mandatory drug holidays: At least 2 weeks every 3 months to prevent tolerance 1
- Taper to lowest effective dose once successful 1
For Depression (Adult)
- Starting dose: 1.0-2.5 mg/kg/day as single bedtime dose 3
- Typical range: 150-300 mg/day 4
- Note: Therapeutic plasma monitoring may be needed; fixed dosing often results in subtherapeutic levels in many patients 5
Absolute Contraindications
Do not prescribe imipramine if ANY of the following are present 2:
- Concurrent MAOI use (requires 14-day washout minimum)
- Acute myocardial infarction recovery period
- Known hypersensitivity to tricyclics
- Personal history of: palpitations, syncope, or cardiac arrhythmias
- Family history of: sudden cardiac death, unstable arrhythmia, or long QT syndrome 1
Required Monitoring
Pre-Treatment (Mandatory)
- ECG to exclude long QT syndrome and rhythm disorders 3 - this is non-negotiable given reports of sudden death in children 3
- Screen for bipolar disorder risk (detailed psychiatric and family history) 2
During Treatment
- Cardiac surveillance at all dose levels for patients with any cardiovascular disease 2
- Monitor for post-void residual urine (risk of UTIs with anticholinergic effects) 1
- Serum level monitoring only if no response at 2.5 mg/kg/day 3
- Close monitoring for suicidality, especially in first few months and with dose changes 2
Common Adverse Effects
Most Problematic Side Effects
Anticholinergic effects (occur early, often before benefits):
- Dry mouth - persistent and specific to imipramine 6
- Constipation - may herald decreasing efficacy 1
- Sweating - enduring burden during maintenance 6
- Tachycardia - persistent throughout treatment 6
- Urinary retention/hesitancy 7, 2
- Blurred vision 8
Other Significant Effects
- Mood changes, nausea, insomnia - often appear before therapeutic benefits 1
- Weight gain - becomes significant with long-term use (>1 year) 6
- Drowsiness 8
- Sexual dysfunction (though may decrease over time) 6
Most Dangerous Effect
Cardiotoxicity with potential fatal overdose 1, 3, 1:
- Risk of conduction defects, arrhythmias, sudden death
- Critical safety measure: Keep medication locked and away from younger siblings 1, 3
- Prescribe smallest quantity possible 2
Clinical Efficacy
- Response rate: 40-60% for both depression and enuresis 3
- Relapse rate: 50% after discontinuation 3
- High tolerance risk - necessitates regular drug holidays 1
- Approximately 50% of children with therapy-resistant enuresis respond 1
Critical Safety Warnings
Suicidality Risk
All patients require close monitoring for emerging suicidality, agitation, panic attacks, insomnia, irritability, hostility, and behavioral changes 2. This risk is highest during initial treatment months and with dose adjustments. Families must provide daily observation and report symptoms immediately.
Drug Interactions
- Methylphenidate inhibits imipramine metabolism - requires downward dose adjustment 2
- Blocks effects of guanethidine and clonidine 2
- Enhances CNS depression with alcohol - increases overdose risk 2
Important Clinical Pitfalls
- Never use as first or second-line therapy - safer alternatives exist for most indications
- Do not skip ECG screening - sudden death risk is real, particularly in children
- Ensure secure storage - accidental ingestion by siblings is the most serious problem 3
- Monitor for constipation - may signal decreasing drug efficacy 1
- Avoid in elderly - tertiary amine TCAs like imipramine have significant anticholinergic burden and are potentially inappropriate per Beers Criteria 9
- Fixed dosing is often inadequate - therapeutic plasma levels (≥200 ng/mL) may require doses ranging from 50-450 mg/day 5